Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Evidence-based guide to rosuvastatin dosing considerations for Hispanic and Latino patients, covering pharmacogenomics, CYP2C9 variants, diabetes prevalence, and clinical trial subgroup data from JUPITER and GALAXY.
Read clinical reviewA clinician-reviewed guide to rosuvastatin dose adjustments, pharmacogenomics, and cardiovascular risk data specific to Black and African ancestry patients, with citations from JUPITER and current ACC/AHA guidelines.
Read clinical reviewA clinical deep-dive into how rosuvastatin (Crestor) performs in Hispanic and Latino patients, covering pharmacogenomics, LDL response differences, CYP2C9 variants, diabetes risk, and evidence-based dosing guidance.
Read clinical reviewRosuvastatin (Crestor) pharmacogenomics, dosing guidance, and safety data specific to Hispanic and Latino patients, with ethnicity-stratified trial evidence and clinical recommendations.
Read clinical reviewA thorough clinical review of rosuvastatin (Crestor) efficacy differences in Black and African ancestry patients, covering JUPITER subgroup data, pharmacogenomics, dosing considerations, and updated ACC/AHA guideline recommendations.
Read clinical reviewEvidence-based review of how rosuvastatin safety, pharmacokinetics, and dosing considerations differ for Black and African ancestry patients, including pharmacogenomic factors and clinical trial subgroup data.
Read clinical reviewSouth Asian patients metabolize rosuvastatin differently due to ABCG2 and SLCO1B1 polymorphisms, leading to higher plasma exposure at standard doses. Evidence-based dosing adjustments and efficacy data reviewed.
Read clinical review